{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T02:57:04Z","timestamp":1773975424756,"version":"3.50.1"},"reference-count":26,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.2748","type":"journal-article","created":{"date-parts":[[2015,2,28]],"date-time":"2015-02-28T22:21:46Z","timestamp":1425162106000},"page":"519-524","source":"Crossref","is-referenced-by-count":10,"title":["Atypical Progressive Multifocal Leukoencephalopathy in a Patient with Antisynthetase Syndrome"],"prefix":"10.2169","volume":"54","author":[{"given":"Moncef","family":"Belhassen-Garcia","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Unit of Infectious Diseases. IBSAL. University Hospital of Salamanca. CIETUS, University of Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Rábano-Gutiérrez","sequence":"additional","affiliation":[{"name":"Department of Neuropathology and Tissue Bank, Research Unit of Alzheimer Project. CIEN Foundation, ISCIII, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Velasco-Tirado","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Unit of Infectious Diseases. IBSAL. University Hospital of Salamanca. CIETUS, University of Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Romero-Alegria","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, IBSAL. University Hospital of Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Luisa","family":"Pérez-Garcia","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, IBSAL. University Hospital of Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Angel","family":"Martin-Oterino","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, IBSAL. University Hospital of Salamanca, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Vandenbroucke E, Grutters JC, Altenburg J, Boersma WG, Borg ter EJ, van den Bosch JMM. Rituximab in life threatening antisynthetase syndrome. Rheumatol Int 29: 1499-1502, 2009.","DOI":"10.1007\/s00296-009-0859-x"},{"key":"2","unstructured":"2. Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol 33: 1021-1026, 2006."},{"key":"3","unstructured":"3. Lambotte O, Kotb R, Maigne G, Blanc F-X, Goujard C, Delfraissy JF. Efficacy of rituximab in refractory polymyositis. J Rheumatol 32: 1369-1370, 2005."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52: 601-607, 2005.","DOI":"10.1002\/art.20849"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gottenberg J-E, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 64: 913-920, 2005.","DOI":"10.1136\/ard.2004.029694"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Brulhart L, Waldburger J-M, Gabay C. Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis 65: 974-975, 2006.","DOI":"10.1136\/ard.2005.045898"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 15: e2-e16, 2011.","DOI":"10.1016\/j.ijid.2010.03.025"},{"key":"8","unstructured":"8. Marie I, Ménard J-F, Hachulla E, et al. Infectious complications in polymyositis and dermatomyositis: a series of 279 patients. Semin Arthritis Rheum 41: 48-60, 2011."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62: 2458-2466, 2010.","DOI":"10.1002\/art.27541"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Manfro RC, Vedolin L, Cantarelli M, Oppitz P, Antunes ACM, Rieder CRM. Progressive multifocal leukoencephalopathy in a kidney transplant recipient after conversion to mycophenolic acid therapy. Transpl Infect Dis 11: 189-190, 2009.","DOI":"10.1111\/j.1399-3062.2009.00368.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Lindå H, Heijne von A, Major EO, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361: 1081-1087, 2009.","DOI":"10.1056\/NEJMoa0810316"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9: 425-437, 2010.","DOI":"10.1016\/S1474-4422(10)70040-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Giraud G, Ramqvist T, Pastrana DV, et al. DNA from KI, WU and Merkel cell polyomaviruses is not detected in childhood central nervous system tumours or neuroblastomas. PloS one 4: e8239, 2009.","DOI":"10.1371\/journal.pone.0008239"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Barzon L, Squarzon L, Militello V, et al. WU and KI polyomaviruses in the brains of HIV-positive patients with and without progressive multifocal leukoencephalopathy. J Infect Dis 200: 1755-1758, 2009.","DOI":"10.1086\/648095"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Barzon L, Squarzon L, Pacenti M, Scotton PG, Palù G. Detection of WU polyomavirus in cerebrospinal fluid specimen from a patient with AIDS and suspected progressive multifocal leukoencephalopathy. J Infect Dis 200: 314-315, 2009.","DOI":"10.1086\/599842"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Lopes da Silva R. Polyoma BK virus: an emerging opportunistic infectious agent of the human central nervous system. Braz J Infect Dis 15: 276-284, 2011.","DOI":"10.1016\/S1413-8670(11)70189-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Weissert R. Progressive multifocal leukoencephalopathy. J Neuroimmunol 231: 73-77, 2011.","DOI":"10.1016\/j.jneuroim.2010.09.021"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tan CS, Dezube BJ, Bhargava P, et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 199: 881-888, 2009.","DOI":"10.1086\/597117"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Amend KL, Turnbull B, Foskett N, Napalkov P, Kurth T, Seeger J. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology 75: 1326-1332, 2010.","DOI":"10.1212\/WNL.0b013e3181f73600"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum 60: 3761-3765, 2009.","DOI":"10.1002\/art.24966"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Koralnik IJ, Boden D, Mai VX, Lord CI, Letvin NL. JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy. Neurology 52: 253-260, 1999.","DOI":"10.1212\/WNL.52.2.253"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Shah R, Bag AK, Chapman PR, Curé JK. Imaging manifestations of progressive multifocal leukoencephalopathy. Clin Radiol 65: 431-439, 2010.","DOI":"10.1016\/j.crad.2010.03.001"},{"key":"23","unstructured":"23. Falcó V, Olmo M, del Saz SV, et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr 49: 26-31, 2008."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Marzocchetti A, Di Giambenedetto S, Cingolani A, Ammassari A, Cauda R, De Luca A. Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy. J Clin Microbiol 43: 4175-4177, 2005.","DOI":"10.1128\/JCM.43.8.4175-4177.2005"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Viallard JF, Lazaro E, Ellie E, et al. Improvement of progressive multifocal leukoencephalopathy after cidofovir therapy in a patient with a destructive polyarthritis. Infection 35: 33-36, 2007.","DOI":"10.1007\/s15010-006-5103-y"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113: 4834-4840, 2009.","DOI":"10.1182\/blood-2008-10-186999"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T12:00:16Z","timestamp":1566388816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/5\/54_54.2748\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.2748","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}